SterisCare's Respicare Inhaler was named the Best New Respiratory Product at Pharma Expo 2025, India's largest pharmaceutical trade exhibition held at Bombay Exhibition Centre, competing against 140+ new product entries across all therapeutic categories.
The Respicare Inhaler delivers Fluticasone/Formoterol in a breath-actuated dry powder inhaler (DPI) format, engineered for consistent dose delivery with a low inhalation resistance — making it accessible to elderly and paediatric patients who struggle with pressurised metered-dose inhalers (pMDIs).
Jury Feedback
The award jury highlighted the inhaler's patient-centric device design, independent dose counter, and compliance-friendly once-daily dosing regimen as differentiating factors from existing market options.
Respicare is currently available across 18 states through our respiratory specialty sales force and will be nationally rolled out through Q1 FY2026-27.
Keywords
